Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Afatinib plus paclitaxel vs investigator's choice chemotherapy after EGFR TKI failure in NSCLC
CTR20131403Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Aug 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of afatinib in non-small cell lung cancer (NSCLC), sponsored by Boehringer Ingelheim. Started Aug 2014; status: completed.
02
Drugs
afatinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20131403.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20131403.